EAM
STLN

Exos Asset Management’s Starling Oncology STLN Stock Holding History

Exos Asset Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,000
Closed -$50K – 381
2021
Q3 		$50K Hold
5,000
– – 0.03% 329
2021
Q2 		$50K Hold
5,000
– – 0.03% 558
2021
Q1 		$50K Buy
+5,000
New +$53.3K 0.04% 296

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Exos Asset Management's STLN Position: Q4 2021 in Review

Exos Asset Management sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 5,000 shares — an estimated $50K sold.

Exos Asset Management first reported a position in STLN in Q1 2021 and held it in 3 quarters. The position peaked at $50K in Q3 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Exos Asset Management reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • Exos Asset Management sold 5,000 Starling Oncology shares in Q4 2021, an estimated $50K.
  • Exos Asset Management first reported a position in Starling Oncology in Q1 2021 and held it in 3 quarters.
  • Exos Asset Management's Starling Oncology position peaked at $50K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Exos Asset Management's 13F filing for Q4 2021, filed 14 Mar 2022.